Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: The impact of pre-lung transplant (LT) pan-drug-resistant Pseudomonas aeruginosa (PDR PsA) colonization on post-LT mortality and bronchiolitis obliterans syndrome (BOS) rates in cystic fibrosis (CF) LT recipients (LTR) is unknown.
Methods: Retrospective, multicenter study from 1/1/2010 to 12/31/2011 of CF LTR with PsA airway colonization within 6 months of LT with 3 years of follow-up post-LT.
Results: 14 centers enrolled 99 LTR (median lung allocation score 40 [IQR 37-51]). 52/99 (53%) LTR had pre-LT PDR PsA. LTR with PDR PsA were older (median age 29 [IQR 25-36] vs 24 years [IQR 19-29], p<0.01), received more peri-LT antibiotics (median 4 [IQR 3-5] vs 3 [IQR 3-4], p<0.01), were more likely to receive induction therapy (88% vs 70%, p=0.02), and had a longer post-LT length of stay (LOS, mean 29 vs 19 days, p<0.05). Rates of BOS (19% vs 36%, [p=0.07]), 3-year mortality (17% vs 30%, [p=0.16]) and time from LT to BOS or death were similar among LTR with vs without PDR PsA.
Conclusions: While PDR PsA colonization is associated with longer post-LT LOS in CF LTR, rates of post-LT BOS and mortality were similar in patients with PDR vs other PsA.
CITATION INFORMATION: Pouch S, Lease E, Bogdanovich T, Ho D, Miller R, Estabrook M, Babu T, Kotton C, Shaver C, Thomas L, Aslam S, McCarty T, Garcia-Diaz J, Doucette K, Kirkby S, van Duin D. Susceptibility Patterns of Pre-Transplant Pseudomonas and Post-Lung Transplant Outcomes in Patients with Cystic Fibrosis. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Pouch S, Lease E, Bogdanovich T, Ho D, Miller R, Estabrook M, Babu T, Kotton C, Shaver C, Thomas L, Aslam S, McCarty T, Garcia-Diaz J, Doucette K, Kirkby S, Duin Dvan. Susceptibility Patterns of Pre-Transplant Pseudomonas and Post-Lung Transplant Outcomes in Patients with Cystic Fibrosis. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/susceptibility-patterns-of-pre-transplant-pseudomonas-and-post-lung-transplant-outcomes-in-patients-with-cystic-fibrosis/. Accessed March 4, 2021.
« Back to 2016 American Transplant Congress